ERBB2 and ovarian cancer: HER2 is overexpressed in 25–30% of breast and ovarian cancers [61], up to 60% of human osteosarcomas (OS) [62], approximately 80% of GBM [63], and 40% of medulloblastomas but is not detected in normal cerebellum and other brain tissues [64].